Denmark’s biotech footprint is expanding, driven by foundation-backed capital allocation, talent depth, and an incubator-to-venture pipeline centered on the Novo Nordisk Foundation ecosystem. Industry participants cited Novo Holdings Seed Investments and the BioInnovation Institute (BII) as key translators of novel academic science into investable companies. The report describes a vertically integrated system—foundation funding for science, BII support for early-stage startups, and Novo Holdings fueling ventures—that differs from models in other European countries. A stated example includes BII’s scale, supporting more than 130 early-stage startups in life science and deep tech, alongside a foundation grant earmarked to elevate innovation in Denmark and Europe.